(Difference between revisions)
- September 23, 2005 - * Special Bioethics Seminar *
Stempsey (College of Holy Cross)
- October 28, 2005 - * Special Bioethics Seminar *
Thomas Shannon (Worcester Polytechnic Institute)
Mark Trusheim (Massachusetts Biotechnology Council) - 56-114 1:30 - 2:30 pm
Dr. Paul Mason (Genzyme)
"Drug discovery at Genzyme"
Dr. Gyan Bhanot (IBM Life Sciences)
"Systems biology and supercomputing at IBM Life Sciences"
Dr. Damon Demady (Biogen Idec)
"Challenges of drug development: By the book vs. reality"
Dr. Jinping Gan (Bristol-Myers Squibb)
"Reactive metabolites in drug discovery"
John Essigmann (MIT BE & CEHS)
"De-mystification of the grant application process for new academic investigators"
Nancy Briefs (President & CEO of Percardia)
"A long winding road: From patent to PMA"
Dr. Can Ozbal (BioTrove Inc.)
"Mass spectroscopy-based label-free ultra-high throughput screening for drug discovery"
Dr. Jonathan Gertler (Adams Harkness)
"Market dynamics & financial strategies in life science technologies"
Dr. Cindy Xia (Millenium)
"From ABC to SLC: Evaluation of drug transporters in drug discovery and development"
Dr. Keith Hoffmaster (Pfizer Inc.)
"ADME in drug discovery & cholestasis as a mechanism of hepatotoxicity"
Drs. Birgit Schoeberl & Brian Harms (Merrimack Pharmaceuticals Inc.)
"Starting a career in industry as an MIT alum"
Dr. Vicki Sato (President of Vertex Pharmaceuticals Inc.)
"Careers in academia & in industry"
- October 5, 2004 (see picture :))
Prof. Michael Lysaght (Brown University)
"After the PhD: Career decisions in biomedical engineering"